心力衰竭

注册

 

发新话题 回复该主题

早期乳腺癌患者接受蒽环类化疗和或曲妥 [复制链接]

1#
北京最好治疗白癜风 http://wapyyk.39.net/bj/zhuanke/89ac7.html


  年5月8日,施普林格·自然旗下《乳腺癌研究与治疗》在线发表韩国首尔高医院的研究报告,通过韩国医疗保险审核评定机构数据库,对早期乳腺癌患者接受蒽环类化疗和(或)曲妥珠单抗治疗所致充血性心力衰竭的发生率、发生时间和风险因素进行了大数据分析。


  该研究从韩国医疗保险审查评定机构数据库列入年1月~年10月被诊断为早期乳腺癌、既往无充血性心力衰竭史、年龄19岁女性患者8万例。


  结果发现充血性心力衰竭发生率:

蒽环类→曲妥珠单抗:6.3%

非蒽环类→曲妥珠单抗:4.2%

蒽环类化疗:3.1%


  术后辅助治疗至充血性心力衰竭发生的中位时间:

蒽环类化疗:大约2年(.0天)

蒽环类→曲妥珠单抗:大约1年(.5天)


  曲妥珠单抗治疗与充血性心力衰竭较早发生相关,无论之前化疗是否蒽环类,但是两个化疗组→曲妥珠单抗治疗后1.2年,充血性心力衰竭的远期风险迅速减少。


  根据多因素比例风险回归分析,卡尔森合并症指数评分≥2的老年患者组(≥65岁)接受蒽环类→曲妥珠单抗后,充血性心力衰竭校正后风险比显著增加。


  因此,该研究表明,对于韩国早期乳腺癌患者,无论之前化疗是否蒽环类,新辅助或辅助化疗→曲妥珠单抗与蒽环类化疗相比,充血性心力衰竭风险显著增加。

BreastCancerResTreat.May8.[Epubaheadofprint]

Incidenceandriskfactorsforcongestiveheartfailureinpatientswithearlybreastcancerwhoreceivedanthracyclineand/ortrastuzumab:abigdataanalysisoftheKoreanHealthInsuranceReviewandAssessmentservicedatabase.

JungYoonChoi,EunYoungCho,YoonJiChoi,JeongHyeonLee,SeungPilJung,KyuRanCho,ChulYongKim,YeulHongKim,KyongHwaPark.

KoreaUniversityAnamHospital,KoreaUniversityCollegeofMedicine,Seoul,Korea.

PURPOSE:Weaimedtoanalyzetheincidence,timetooccurrence,andcongestiveheartfailure(CHF)riskfactorsforearlybreastcancerpatientstreatedwithanthracycline(AC)-basedchemotherapyand/ortrastuzumab(T)therapyinKorea.

METHODS:Weincludedfemalepatients19yearsoldfromtheHealthInsuranceReviewandAssessmentServicedatabasewhohadnopriorCHFhistoryandhadbeendiagnosedwithearlybreastcancerbetweenJanuaryandOctober.

RESULTS:Weincluded83,patientsinouranalysis.IntermsofcrudeincidenceforCHF,ACfollowedbyTshowedthehighestincidence(6.3%).However,3.1and4.2%ofthepatientshadCHFduetoAC-basedchemotherapyandnon-ACfollowedbyT,respectively.ThemediantimestooccurrenceofCHFweredifferentaccordingtoadjuvanttreatments,approximately2years(.0days)intheAC-basedchemotherapygroupvs1year(.5days)ACfollowedbyTgroup.TtherapywasassociatedwithearlierdevelopmentofCHFirrespectiveofpreviouschemotherapy,butlateriskofCHF1.2yearsafterTtherapyrapidlydecreasedinbothchemotherapygroups.MultivariateCoxregressionanalysisrevealedthattheadjustedhazardratioforCHFwasincreasedinthegroupofolderpatients(≥65yearsold)whounderwentACfollowedbyTtherapy,withCharlson

分享 转发
TOP
发新话题 回复该主题